BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 7664272)

  • 21. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins.
    Diah SK; Smitherman PK; Aldridge J; Volk EL; Schneider E; Townsend AJ; Morrow CS
    Cancer Res; 2001 Jul; 61(14):5461-7. PubMed ID: 11454692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.
    Fujimori A; Gupta M; Hoki Y; Pommier Y
    Mol Pharmacol; 1996 Dec; 50(6):1472-8. PubMed ID: 8967967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.
    Lansiaux A; Léonce S; Kraus-Berthier L; Bal-Mahieu C; Mazinghien R; Didier S; David-Cordonnier MH; Hautefaye P; Lavielle G; Bailly C; Hickman JA; Pierré A
    Mol Pharmacol; 2007 Aug; 72(2):311-9. PubMed ID: 17494837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
    Sukhanova A; Grokhovsky S; Zhuze A; Devy J; Pluot M; Oleinikov V; Nabiev I
    Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.
    Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J
    Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Poisons of DNA topoisomerases I and II].
    Charcosset JY; Soues S; Laval F
    Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.
    Devy J; Wargnier R; Pluot M; Nabiev I; Sukhanova A
    Anticancer Res; 2004; 24(3a):1745-51. PubMed ID: 15274350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line.
    Hazlehurst LA; Foley NE; Gleason-Guzman MC; Hacker MP; Cress AE; Greenberger LW; De Jong MC; Dalton WS
    Cancer Res; 1999 Mar; 59(5):1021-8. PubMed ID: 10070958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
    Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
    Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
    Goldwasser F; Bae I; Fornace AJ; Pommier Y
    Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines.
    Vanhoefer U; Müller MR; Hilger RA; Lindtner B; Klaassen U; Schleucher N; Rustum YM; Seeber S; Harstrick A
    Br J Cancer; 1999 Dec; 81(8):1304-10. PubMed ID: 10604726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I.
    Gupta RS; Gupta R; Eng B; Lock RB; Ross WE; Hertzberg RP; Caranfa MJ; Johnson RK
    Cancer Res; 1988 Nov; 48(22):6404-10. PubMed ID: 2846151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone.
    Dalton WS; Cress AE; Alberts DS; Trent JM
    Cancer Res; 1988 Apr; 48(7):1882-8. PubMed ID: 2894893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
    Brangi M; Litman T; Ciotti M; Nishiyama K; Kohlhagen G; Takimoto C; Robey R; Pommier Y; Fojo T; Bates SE
    Cancer Res; 1999 Dec; 59(23):5938-46. PubMed ID: 10606239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content.
    Woessner RD; Eng WK; Hofmann GA; Rieman DJ; McCabe FL; Hertzberg RP; Mattern MR; Tan KB; Johnson RK
    Oncol Res; 1992; 4(11-12):481-8. PubMed ID: 1338578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression.
    Harker WG; Slade DL; Dalton WS; Meltzer PS; Trent JM
    Cancer Res; 1989 Aug; 49(16):4542-9. PubMed ID: 2568172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines.
    Sugimoto Y; Tsukahara S; Oh-hara T; Liu LF; Tsuruo T
    Cancer Res; 1990 Dec; 50(24):7962-5. PubMed ID: 2174738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
    Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
    Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
    Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
    Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.